Introduction
Non-Hodgkin's lymphomas (NHL) encompass a great number of histologic subtypes with marked biological heterogeneity and variable clinical behavior [1] . Globally, these neoplasms are highly responsive to chemotherapy but the majority of patients with advanced disease will relapse and require salvage treatment. Second-line conventional combinations including cisplatin-based regimens have limited efficacy, while high-dose chemotherapy with bone marrow support can produce second durable complete remissions in a significant number of selected patients [2, 3] . New drugs need to be tested in such a patient population.
Oxaliplatin (L-OHP) is a new platinum derivate of the diaminocyclohexamine (DACH) family [4] . Its spectrum of cytotoxicity is different from that of cisplatin and carboplatin in the National Cancer Institute screening panel, and non-cross-or partial cross-resistance with cisplatin in many cell lines and in vivo models [5] . At the recommended dose (130 mg/m q three weeks) it has no renal or auditory, and only minor hematological, toxic effects [4] . Clinical antitumoral activity was shown in a variety of solid tumors including primary (colon cancer) and secondary cisplatin/carboplatin refractory tumors (ovarian cancer) [4, 6, 7] . Our institution has been involved in the clinical development of this platinum analog over the past decade [8, 9] . We had the opportunity to propose this new anticancer agent to patients with recurrent, progressive NHL on an individual compassionate-use basis. We report here the final complete results of this monocentric clinical experience.
Patients and methods

Patient eligibility
Patients with histologically documented non-Hodgkin's lymphomas who had either failed to respond to primary chemotherapy or relapsed Abbreviations: CR -complete response; PR -partial response; SD stable disease, PD -pregression.
rently used oxaliplatin specific neurotoxicity scale was not available at the time of the present experience). Response to treatment was assessed monthly by clinical examination and after at least two cycles by CT scan, echosonography and endoscopy. Patients who received at least two cycles of Oxaliplatin were assessable for response. Responses were defined according to WHO guidelines [10] . Duration of response was measured from the first day of treatment to the date of progression (PD) or last follow-up evaluation. Survival was calculated from treatment onset until death, or last censored follow-up after a response to prior chemotherapy were eligible for this program after providing their informed consent. All had previously received a minimum of one chemotherapy regimen and had progressive disease when they entered the study. Patients who never achieved an objective response to chemotherapy or failed their last chemotherapy regimen were considered to have refractory disease, while those with a response to their last chemotherapy lasting Js6 months were reported to have recurrent tumor. Initial staging included physical examination, complete blood cell count, serum lactate deshydrogenase (LDH), creatininemia, liver function tests, electrolytes and either computed tomographic (CT) scans or echosonography, and endoscopy if necessary. Available biopsies were submitted for central pathology review. Additional immunohistochemical analyses were performed; the panel of monoclonal antibodies used included: CD3, CD5, CD20. CD23, bcl-2 and cyclin Dl. Previous diagnoses were reformulated according to the R.E.A.L. Classification [1] . Other selection criteria for this therapy were as follows: measurable/evaluable disease, performance status (PS) 0-3. pretreatment granulocyte count >1000/ul, platelet count > 100000/ul and creatininemia < 2 times the upper normal limit.
Treatment schedule
Oxaliplatin. supplied by Debiopharm (Lausanne, Switzerland) was diluted in 500 ml 5% dextrose and administered as a two-hour intravenous infusion, repeated every three weeks, in an ambulatory setting. The initial starting dose was 100-130 mg/m 2 . Prophylactic antiemetics were given systematically (metoclopramide and/or HT3 antagonists).
Toxicity and activity assessment All toxicities were graded according to WHO criteria, except for neurotoxicity which was evaluated by the NCI'CTC scale (the cur-
Results
From July 1988 to February 1994, 22 patients entered this study; their characteristics are listed in Table 1 . Median performance status was 0 (1-3). All cases were of B-cell phenotype. According to the R.E.A.L. Classification, the most frequent type was follicular lymphoma (eight patients). In three cases, the histologic subtype was not assessable because of insufficient material for immunohistochemistry examination. Fifteen patients (68%) underwent repeat biopsies before inclusion to exclude or confirm transformation to another histologic type, while the other patients had no signs suggesting a recent phenotypic change in their disease. Eleven patients (50%) had cytologically-or histologically-confirmed bone marrow involvement. Nine patients (40%) had extranodal dominant disease, including five with either gastric or colon involvement. Six of 21 (28.5%) patients had elevated LDH. All were pretreated, with a median number of prior chemotherapies of 2 (1-7). Eighteen (80%) had received one anthracycline-based regimen while all were previously given ^ 1 alkylating agent, including cisplatin in four instances. The median time from the last chemotherapy regimen was 2 months (1-66). Fourteen patients (63%) were considered to have chemo-refractory disease. Eleven patients (50%) had had prior radiation.
Activity
A total of 144 cycles of oxaliplatin were given, with a median number of 6 cycles (1-30) per patient. The initial starting dose was 100 mg/m 2 in six patients, and 130 mg/m 2 in 15 patients; the first patient, treated during the early development of oxaliplatin, received 70 mg/m 2 in his first four treatment cycles. The median dosage per cycle was 100 mg/m 2 (70-130). All patients were assessable for response. Nine patients (40%, 95% CI: 21%-64%) achieved objective responses to this treatment, one complete response (CR) and eight partial responses (PR). Five of 14 (36%) patients with refractory disease achieved responses while four of eight (50%) with relapsed lymphoma responded to treatment (ns). One of the four patients previously treated with cisplatin had a complete response of 16 months' duration; this patient received oxaliplatin as a third-line chemotherapy for a recurrent mantle-cell lymphoma (MCL) since she had failed to respond to the DHAP regimen two months earlier. The patient characteristics of the responders are detailed in Table 2 . The median duration of response was 27 months (5-44). As of April 1998, with a median followup of 80 months, 16 patients had died, four patients were still alive, while two were lost to follow-up. The median survival of the group as a whole was 23 months.
Safety
All patients are evaluable for toxicity. Treatment was well tolerated. Complete blood counts and blood biochemistry were required only on the day of therapy (day 21). Myelosupression may have been underestimated, with grade 3-4 hematological toxicity reported in only three patients including grade 3 neutropenia (two patients) and grade 3 thrombopenia (one patient). Grade 3 nausea/vomiting was registered in three patients, the majority presenting a grade 1-2 gastrointestinal toxicity. Two patients had episodes of grade 2 diarrhea. Most patients experienced neurological toxicity, limited to a grade 1-2 peripheral neuropathy including cold-induced dysesthesias and paresthesias. Two patients, who had received, respectively, seven and 14 cycles of oxaliplatin (cumulative doses of 910 and 1400 mg/m 2 ) presented grade 3 cumulative, reversible neuropathies; the latter patient received his first cycle of oxaliplatin while presenting persistent grade 2-3 neuropathy secondary to prior treatment with vinorelbin. Another patient was given a total of 30 cycles (3 g/m 2 ) over 36 months, his maximal neuropathy was grade 1.
Discussion
In this pilot study, oxaliplatin demonstrated an interesting antitumoral activity (40% overall response rate ORR) in pretreated patients. Patients with recurrent as well as those with refractory disease responded to oxaliplatin. Responses were of long duration, and observed in different histologic subgroups; noteworthy is that three of five patients with MCL responded to oxaliplatin, including one with a complete response. One patient with cisplatin-refractory disease responded to oxaliplatin.
Oxaliplatin was well tolerated in this pretreated population, including 50% of patients with bone marrow infiltration. Neurotoxicity was limited to a mild/moderate peripheral sensitive neuropathy. This safety profile makes this agent a good therapeutic alternative in heavily pretreated patients. Finally, the activity of L-OHP as single-agent compared favorably with those previously reported with cisplatin alone in a similar patient population [11, 12] . However, additional formal phase II studies are needed to confirm these preliminary encouraging results in a larger patient population. New oxaliplatinbased salvage regimens should only then be explored.
